CymitQuimica logo

CAS 216974-75-3

:

Bevacizumab

Description:
Bevacizumab is a monoclonal antibody used primarily in cancer therapy, specifically targeting vascular endothelial growth factor (VEGF). By inhibiting VEGF, it disrupts the formation of new blood vessels (angiogenesis) that tumors require for growth and metastasis. This drug is often employed in the treatment of various cancers, including colorectal, lung, and breast cancers. Bevacizumab is administered via intravenous infusion and is typically used in combination with other chemotherapy agents to enhance therapeutic efficacy. Its mechanism of action involves binding to VEGF, preventing it from interacting with its receptors on endothelial cells, thereby inhibiting tumor vascularization. Common side effects may include hypertension, increased risk of bleeding, and gastrointestinal perforations. As a biologic agent, Bevacizumab is produced through recombinant DNA technology, and its stability and efficacy are influenced by storage conditions and handling. The drug is classified under the category of anti-angiogenic agents and has been a significant advancement in targeted cancer therapies, contributing to improved patient outcomes in various malignancies.
Formula:C6638H1016N1720O2108S44
Synonyms:
  • Bevacizumab
  • Avastin
  • BevacizuMab [USAN:INN]
  • Rhumab-vegf
  • Bevacituzumab
  • Unii-2S9zzm9Q9v
  • Bevacizumab USP/EP/BP
  • Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhumab-vegf gamma1-chain), disulfide with human-mouse monoclonal rhumab-vegf light chain, dimer
  • Bevacizumab (Avastin)
  • Bevacizumab(anti-VEGF)
  • See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.